BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 20846101)

  • 1. What's new in Waldenström macroglobulinemia.
    Gertz MA
    Leuk Lymphoma; 2010 Oct; 51(10):1765-6. PubMed ID: 20846101
    [No Abstract]   [Full Text] [Related]  

  • 2. Unresolved issues in the comparison of therapies and determination of responses in Waldenström macroglobulinemia.
    Peinert S; Seymour JF
    Leuk Lymphoma; 2010 Oct; 51(10):1767-70. PubMed ID: 20919859
    [No Abstract]   [Full Text] [Related]  

  • 3. Review of clinical trials conducted in Waldenstrom macroglobulinemia and recommendations for reporting clinical trial responses in these patients.
    Rourke M; Anderson KC; Ghobrial IM
    Leuk Lymphoma; 2010 Oct; 51(10):1779-92. PubMed ID: 20795787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Waldenstrom's macroglobulinemia: is there a place and time for a cease-fire?
    Zinzani PL; Tani M; Alinari L; Stefoni V; Baccarani M
    Leuk Res; 2003 May; 27(5):465-6. PubMed ID: 12620298
    [No Abstract]   [Full Text] [Related]  

  • 5. Fludarabine in Waldenstrom's macroglobulinemia.
    Souchet-Compain L; Nguyen S; Choquet S; Leblond V
    Expert Rev Hematol; 2013 Jun; 6(3):229-37. PubMed ID: 23782076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Waldenstrom macroglobulinemia].
    Kolyvanos Naumann U; Käser L; Vetter W
    Praxis (Bern 1994); 2004 Mar; 93(14):547-52, 577. PubMed ID: 15125068
    [No Abstract]   [Full Text] [Related]  

  • 7. Waldenström's macroglobulinemia.
    Desikan KR; Dhodapkar MV; Barlogie B
    Curr Treat Options Oncol; 2000 Jun; 1(2):97-103. PubMed ID: 12057047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Therapy of Waldenström´s macroglobulinaemia in the year 2014].
    Adam Z; Krejčí M; Pour L; Ševčíková E
    Vnitr Lek; 2014 Feb; 60(2):139-57. PubMed ID: 24754419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fludarabine in Waldenstrom's macroglobulinemia.
    Leblond V; Choquet S
    Semin Oncol; 2003 Apr; 30(2):239-42. PubMed ID: 12720144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment options in Waldenström's macroglobulinaemia: the role of the purine analogues.
    Owen RG
    Expert Opin Pharmacother; 2001 Jun; 2(6):945-52. PubMed ID: 11585010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2-Chlorodeoxyadenosine treatment of lymphoma.
    Saven A; Piro LD
    Cancer Treat Res; 1996; 85():15-26. PubMed ID: 9043772
    [No Abstract]   [Full Text] [Related]  

  • 12. Waldenström's macroglobulinemia.
    McKenna JA
    Clin J Oncol Nurs; 2002; 6(5):283-6. PubMed ID: 12240489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab-based treatments in Waldenström's macroglobulinemia.
    Dimopoulos MA; Kastritis E; Roussou M; Eleutherakis-Papaiakovou E; Migkou M; Gavriatopoulou M; Tassidou A; Terpos E
    Clin Lymphoma Myeloma; 2009 Mar; 9(1):59-61. PubMed ID: 19362975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Waldenstrom's macroglobulinemia with nucleoside analogues.
    Dimopoulos MA; O'Brien S; Kantarjian H; Estey EE; Keating MJ; Alexanian R
    Leuk Lymphoma; 1993; 11 Suppl 2():105-8. PubMed ID: 7907250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Guidelines on the management of Waldenström macroglobulinaemia.
    Johnson SA; Birchall J; Luckie C; Oscier DG; Owen RG;
    Br J Haematol; 2006 Mar; 132(6):683-97. PubMed ID: 16487169
    [No Abstract]   [Full Text] [Related]  

  • 16. Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenström macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma.
    Leblond V; Johnson S; Chevret S; Copplestone A; Rule S; Tournilhac O; Seymour JF; Patmore RD; Wright D; Morel P; Dilhuydy MS; Willoughby S; Dartigeas C; Malphettes M; Royer B; Ewings M; Pratt G; Lejeune J; Nguyen-Khac F; Choquet S; Owen RG
    J Clin Oncol; 2013 Jan; 31(3):301-7. PubMed ID: 23233721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab-induced life-threatening coagulopathy occurring in a patient with Waldenström macroglobulinemia treated with fludarabine, cyclophosphamide, and rituximab combination.
    Pilorge S; Park S; Dreyfus F; Bouscary D; Tamburini J
    Leuk Lymphoma; 2010 Dec; 51(12):2288-90. PubMed ID: 20929331
    [No Abstract]   [Full Text] [Related]  

  • 18. Phase III study of chlorambucil versus fludarabine as initial therapy for Waldenstrom's macroglobulinemia and related disorders.
    Johnson SA; Owen RG; Oscier DG; Leblond V; Levy V; Jaeger U; Seymour JF
    Clin Lymphoma; 2005 Mar; 5(4):294-7. PubMed ID: 15794869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current results and prospective trials of cladribine in chronic lymphocytic leukemia.
    Tallman MS; Hakimian D
    Semin Hematol; 1996 Jan; 33(1 Suppl 1):23-7. PubMed ID: 8714613
    [No Abstract]   [Full Text] [Related]  

  • 20. The optimized anti-CD20 monoclonal antibody ublituximab bypasses natural killer phenotypic features in Waldenström macroglobulinemia.
    Le Garff-Tavernier M; Herbi L; de Romeuf C; Azar N; Roos-Weil D; Bonnemye P; Urbain R; Leblond V; Merle-Beral H; Vieillard V
    Haematologica; 2015 Apr; 100(4):e147-51. PubMed ID: 25552707
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.